Living with a severe food allergy can be frightening. While new treatments like omalizumab and oral immunotherapy are available, doctors face a difficult challenge when deciding the best path forward for an individual patient. The current landscape of care lacks a standardized way to measure risk before starting these therapies.
The review looked at how different innovations, such as intranasal epinephrine and combination approaches, fit into current medical practice. It highlighted that while many options exist, there are no validated tools to help doctors predict which patients might face the most risk during treatment. This makes it harder to create a personalized plan for every person.
Because these specific risk-stratification tools are missing, doctors must rely on general clinical knowledge rather than data-driven safety markers. The goal is to develop a framework that uses patient characteristics and biomarkers to make safer, more individualized decisions for those living with IgE-mediated food allergies.
